Drugs / HEPATOPOIETIN-A
HEPATOPOIETIN-A
also known as
Hepatocyte growth factor · KP-100IT · HGF · KP-100LI · Recombinant human hepatocyte growth factor
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00225901 | Sep 2005 → ? | acute liver failure | Kyoto University, Graduate School of Medicine | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04475224 | Jul 2020 → Dec 2022 | spinal cord injury | Kringle Pharma, Inc. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02193334 Comparator | Jun 2014 → Dec 2017 | spinal cord injury | Kringle Pharma, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05627648 Comparator | Dec 2022 → Jul 2026 overdue | — | Kringle Pharma, Inc. | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04906083 Background | Feb 2021 → Dec 2022 | cirrhosis of liver, liver failure, thrombocytopenia | Tongji Hospital | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEPATOPOIETIN-A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298081 ↗ |
| Known as | Hepatocyte growth factor | “Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.” NCT04906083 ↗ |
| Known as | HGF | “Hepatocyte growth factor (HGF) is one of major agents stimulating liver regeneration and ameliorating hepatic injury.” NCT00225901 ↗ |
| Known as | KP-100IT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02193334 ↗ |
| Known as | KP-100LI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05627648 ↗ |
| Known as | Recombinant human hepatocyte growth factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298081 ↗ |
| Modality | Protein / enzyme biologic | “In this study, recombinant human HGF is administered to patients with fulminant hepatic failure or LOHF.” NCT00225901 ↗ |
| Route | Intrathecal | “Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times” NCT02193334 ↗ |